Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomaximaFRA:944 +0.20%60 EV-to-EBIT is 56.04 as of Sep. 01, 2026, which is 254% above its 10-year median of 15.84. GuruFocus rates FRA:944 with a GF Score™ of 60/100 and a GF Value™ of €2.93. The stock has 4 warning signs investors should review. Among 107 Medical Diagnostics & Research companies, Biomaxima ranks worse than 87.85% on this metric.
The historical rank and industry rank for Biomaxima's EV-to-EBIT or its related term are showing as below:
FRA:944'
s EV-to-EBIT Range Over the Past 10 Years
Min: -648.3 Med: 15.84 Max: 440.95
Current: 57.07
During the past 13 years, the highest EV-to-EBIT of Biomaxima was 440.95. The lowest was -648.30. And the median was 15.84.
FRA:944's EV-to-EBIT is ranked worse than 87.85% of 107
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.19
vs FRA:944: 57.07
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Biomaxima's Enterprise Value for the quarter that ended in Mar. 2026 was €12.94 Mil.
Biomaxima's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomaxima EV-to-EBIT Related Terms
Biomaxima EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Biomaxima's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Biomaxima's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomaxima EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomaxima's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Biomaxima's EV-to-EBIT falls into.
Biomaxima's current Enterprise Value is €13.39 Mil.
Biomaxima's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomaxima (FRA:944) has a EV-to-EBIT of 56.04 as of Sep. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biomaxima and its competitors. This is 254% above median its historical median of 15.84. According to the industry distribution chart, Biomaxima ranks #94 out of 107 companies in the Medical Diagnostics & Research industry, placing it in the top 87.9%.
Is Biomaxima's EV-to-EBIT too high?
Biomaxima's current EV-to-EBIT of 56.04 is 254% above median its 10-year median of 15.84. The Medical Diagnostics & Research industry median EV-to-EBIT is 24.19. Biomaxima's value of 56.04 is 131.7% above this industry median. Based on the distribution chart, Biomaxima ranks #94 out of 107 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Biomaxima has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Biomaxima's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomaxima ranks #94 out of 107 companies for EV-to-EBIT. This places Biomaxima in the lower half of its industry. The industry median EV-to-EBIT is 24.19. Biomaxima's value of 56.04 is 131.7% above this benchmark. While the company's 10-year median is 15.84 vs. the industry median of 24.19, Biomaxima has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 24.19, based on 107 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomaxima's current EV-to-EBIT of 56.04 is 131.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biomaxima and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 24.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomaxima's current EV-to-EBIT is 56.04, which is 254% above median its own 10-year median of 15.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomaxima stock overvalued right now?
Biomaxima (FRA:944) has a current EV-to-EBIT of 56.04. The stock's GF Value™ is €2.93, compared to a current price of €1.98 — trading 32.5% below its estimated fair value. The current EV-to-EBIT is 56.04, which is 254% above median its 10-year median of 15.84 and 131.7% above the Medical Diagnostics & Research industry median of 24.19. Biomaxima's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Biomaxima (FRA:944), the current EV-to-EBIT is 56.04 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomaxima (FRA:944) Overvalued in 2026?
Based on GuruFocus' analysis, Biomaxima stock appears to be undervalued.
The current stock price of €1.98 is trading 32.5% below its estimated GF Value™ of €2.93.
Key valuation signals for FRA:944:
EV-to-EBIT: 56.04 (254% above median its 10-year median of 15.84)
GF Value™: €2.93 vs. price of €1.98 (32.5% below fair value)
Industry Position: 131.7% above the Medical Diagnostics & Research median (#94 of 107)
No single metric tells the full story. See the FRA:944 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog.
60GF Score
Get the complete analysis for FRA:944
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:944 has been successfully added to your 
